Human Microbiome: How Bacteria Affect Health and Immunity

Gut microbiota dysbiosis—defined as microbial community imbalance—is a fundamental mechanism underlying multiple chronic inflammatory and autoimmune diseases. Research reveals consistent patterns: decreased microbial diversity, increased pathogenic bacteria (Enterobacteriaceae, E. coli), and reduced beneficial organisms (Clostridium coccoides, Bacteroides, Faecalibacterium prausnitzii). This dysbiotic state contributes through impaired intestinal barrier function ('leaky gut'), immune system activation (both innate and adaptive), and subsequent tissue destruction. Beyond IBD, dysbiosis is implicated in colon cancer, multiple sclerosis, ankylosing spondylitis, obesity, type 2 diabetes, and metabolic syndrome. The gut-microbiome-immune axis represents a unifying framework connecting seemingly disparate chronic diseases, suggesting that restoring microbial homeostasis may offer broad therapeutic potential across multiple disease categories.

When pathogenic bacteria outnumber beneficial bacteria, microbiota composition alters, a condition known as intestinal disbiosis. This is clearly related to inflammatory bowel disease, obesity, and potentially all chronic diseases, including bone diseases, immunological diseases, and inflammatory conditions.

Inflammatory bowel disease (IBD) involves abnormal immune activation against the gut microbiome in genetically susceptible individuals under environmental influences. The microbiome in IBD becomes dysbiotic, characterized by reduced diversity (fewer species) and altered composition. Healthy individuals show distinct microbiome profiles compared to IBD patients, with active disease showing the greatest differences. Patients in remission show intermediate profiles. The imbalance involves excessive pro-inflammatory bacteria stimulating the immune system and diminished regulatory bacteria that maintain balance. This dysbiosis is thought to contribute to both disease initiation and chronicity, making microbiome restoration a therapeutic goal.

Dysbiosis represents a departure from healthy microbiome characterized by reduced diversity, pathogenic organism expansion, and loss of commensal populations, occurring in genetically susceptible hosts. Multiple mechanisms explain microbiome-driven autoimmunity: molecular mimicry where bacterial peptides resemble self-peptides, citrullination (arginine-to-citrulline substitution) creating foreign-detected proteins particularly relevant in RA, superantigens excessively stimulating the immune system, and epitope spreading expanding immune recognition to multiple proteins. Remarkably similar dysbiosis patterns appear across inflammatory conditions including IBD, multiple sclerosis, RA, and lupus, suggesting common underlying mechanisms. Experimental evidence using germ-free mice demonstrates that genetically susceptible mice do not develop autoimmune diseases unless exposed to specific bacteria. Spondyloarthritis shows strong IBD links with reduced diversity, while RA exhibits strong periodontal disease links through Porphyromonas gingivalis-induced citrullination. Prevotella copri shows significantly increased abundance in new-onset RA patients, decreasing after treatment when disease is controlled.

Dysbiosis is an imbalance in the gut microbiome where harmful bacteria, yeast, or parasites overgrow, disrupting the delicate balance of beneficial bacteria; this condition is linked to numerous health problems including obesity, diabetes, heart disease, autoimmune disorders, mood disorders, and various infections, and can be caused by factors such as antibiotics, poor diet, stress, and infections, but is treatable through dietary changes, probiotics, herbal antimicrobials, and lifestyle modifications.

Three main strategies manipulate the microbiome: prebiotics (non-digestible dietary fibers promoting beneficial bacterial growth), probiotics (live exogenous bacteria modulating inflammation and barrier function), and fecal microbiota transplantation (FMT). FMT involves infusing liquid suspension of healthy donor stool to restore normal gut microbiota. A landmark NEJM trial in 2013 demonstrated superior efficacy compared to standard vancomycin therapy alone for recurrent Clostridioides difficile infection, with success rates exceeding 95% in clinical programs. The procedure typically uses colonoscopic delivery, with restoration of microbiota diversity confirmed through 16S rRNA sequencing. Beyond C. difficile, emerging evidence suggests FMT may restore gut homeostasis and reduce infections with multi-drug resistant organisms in transplant patients, representing a paradigm shift in microbiota-based therapeutics.

Restoring microbiota health offers promising therapeutic interventions. Prebiotics are dietary fibers and polyphenols that nourish beneficial bacteria—humans should consume approximately 20% of food as prebiotics but achieve only 1-5%. Jerusalem artichokes, parsnips, asparagus, chicory, garlic, onions, bananas, apples, pomegranates, berries, and turmeric are excellent prebiotic foods. Probiotics are live beneficial bacteria, though many commercial products contain only a few strains and may not suit every individual. Fecal microbiota transplantation (FMT) transfers healthy donor microbiota to recipients, achieving approximately 90% success rates for Clostridium difficile infections previously resistant to all antibiotics. This revolutionary treatment demonstrates that microbiota restoration can cure conditions once considered untreatable. Personalized approaches considering individual microbiota profiles offer more effective solutions than standardized supplements. The Cleveland Clinic recognized gut microbiota importance as one of the top medical innovations. Not only do all diseases begin in the gut, but all diseases begin when the microbiota has not been respected.

Most commercial probiotics fail to colonize the gut due to competition from established species and lack of native gut origins, passing through within 3-5 days. However, specific strains like Bifidobacterium longum (a top 50 gut species) can persist for six months when administered appropriately. Fecal microbiota transplant has become standard therapy for recurrent C. diff infections, achieving 85-95% cure rates. Over 400 clinical trials now explore FMT for various conditions. A 3-week non-industrialized diet trial demonstrated remarkable benefits: weight loss, 17% cholesterol reduction, 6% blood glucose decrease, 14% lower inflammation markers, and increased production of neuroprotective metabolites like indole-3-propionic acid. These findings suggest diet functions as microbiome nutrition, where feeding microbes appropriate nutrients transforms their functional output.

Three main categories of microbiota-targeting therapies exist. Probiotics contain live bacteria that colonize the gut and replace damaged microbiota, used primarily for treating dysbiosis after antibiotic courses. Prebiotics serve as food for beneficial bacteria, promoting their growth and used for prevention. Synbiotics combine both, useful for mild cases and allowing reduced dosing. Pharmaceutical preparations undergo stricter quality control than supplements, which may contain harmful additives. For prevention, natural prebiotics like buckwheat and bran bread are recommended, while pharmaceutical prebiotics address minimal symptoms.

Metagenomics studies genetic material from environmental samples, enabling analysis of the ~99% of bacteria that cannot be cultured in labs. Two main approaches exist: 16S rRNA amplicon sequencing (cheap, well-established, provides taxonomic composition but no functional data) and shotgun sequencing (expensive, provides comprehensive genetic and functional information). The 16S gene (1,500 bp) contains conserved and variable regions; V3-V4 regions are most common for bacterial profiling. Key challenges include compositionality (relative abundances are interdependent), sparsity (many zeros with ambiguous meaning), and variable sequencing depth across samples.

Metagenomics is the study of genetic material from entire microbial communities, revolutionized by decreasing DNA sequencing costs from $10,000 per megabase in 2000 to approximately one cent today. Two primary approaches exist: 16S rRNA sequencing, which targets a highly conserved bacterial gene with variable regions for species identification at genus level; and shotgun metagenomics, which sequences all DNA in a sample for unbiased, higher-resolution analysis down to species or strain level. While 16S costs $40-45 per sample, shotgun sequencing costs $200+ per sample but provides more comprehensive insights into microbial communities, including detection of fungi, viruses, and bacteriophages that 16S cannot identify.

This section introduces two fundamental approaches for analyzing microbial communities. 16S rRNA gene sequencing targets a single conserved gene across all bacteria, providing cost-effective taxonomic profiles (~$20 for ~50,000 sequences) but suffers from primer bias, inability to detect non-bacterial microbes, and limited functional information. In contrast, shotgun metagenomics sequences all DNA in a sample, capturing complete microbial communities including host contamination (up to 95% in biopsy samples) with no primer bias. Beyond taxonomy, shotgun approaches enable functional annotation by identifying which genes are present. Machine learning applications, particularly random forest classifiers, combine genetic risk scores, 16S profiles, and shotgun functional data to predict disease states and treatment outcomes, achieving ~84% accuracy in distinguishing pediatric Crohn's patients from controls.

Metagenomics studies genetic material directly from environmental samples, enabling analysis of microbial communities without culturing individual organisms. This approach addresses two core questions: identifying community composition ('who is there?') and understanding functional activities ('what are they doing?'). Two main approaches exist: targeted/amplicon sequencing using PCR to amplify marker genes like the 16S rRNA gene (~1500 nucleotides with conserved and hypervariable regions for classification), and shotgun metagenomics sequencing all genomes for comprehensive analysis. The 16S rRNA workflow includes PCR amplification of V3-V4 regions, library prep, sequencing, and bioinformatics analysis using tools like the Illumina 16S Metagenomics App. Analysis involves trimming reads, classifying against curated databases (Greengenes, RDP, UNITE), and generating interactive visualizations including sunburst charts and bar charts showing relative abundances at different taxonomic levels.

This video introduces metagenomics, focusing on 16S rRNA amplicon sequencing for studying microbial communities. The 16S rRNA gene, approximately 1500 base pairs long, contains conserved regions (30-100 bp) separated by variable regions (V1-V9) that enable taxonomic classification. The analysis pipeline includes quality control, paired-read merging, operational taxonomic unit (OTU) assignment, chimera removal, and phylogenetic tree construction. Statistical methods like non-metric multidimensional scaling (NMDS) help visualize community composition differences between samples. The microbiome includes bacteria, archaea, viruses, and fungi, with composition varying across body sites based on environmental conditions like pH and oxygen levels. Major research initiatives like the NIH Human Microbiome Project and American Gut Project have established baseline microbiome profiles for understanding health and disease relationships.